---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-139146"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T13:46:21.738523+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns

## Summary
- Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.
- Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.
- Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.
- She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.
- Board determined Dr. Mazumdar is independent under Nasdaq listing standards.

## SEC filing metadata
- accession: 0001193125-25-139146
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/0001193125-25-139146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/d948938d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-139146
- JSON: https://secwatch.observer/filing/0001193125-25-139146.json
- Plain text: https://secwatch.observer/filing/0001193125-25-139146.txt

## Key facts
- Executive change
  Claire Mazumdar was appointed as Class III Director at Relay Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph.D., MBA as a member of the Board, effective as of June 9, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/0001193125-25-139146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.